These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 11081814

  • 21. Glatiramer acetate: a novel therapeutic approach in Crohn's disease?
    Neesse A, Michl P, Kunsch S, Gress TM, Steinkamp M.
    Inflamm Bowel Dis; 2009 Jan; 15(1):156-7. PubMed ID: 18626969
    [No Abstract] [Full Text] [Related]

  • 22. Localized lipoatrophy after prolonged treatment with copolymer 1.
    Mancardi GL, Murialdo A, Drago F, Brusati C, Croce R, Inglese M, Ratto S.
    J Neurol; 2000 Mar; 247(3):220-1. PubMed ID: 10787120
    [No Abstract] [Full Text] [Related]

  • 23. Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy.
    Hotermans C, Belachew S, Moonen G, Delwaide J.
    Mult Scler; 2009 Nov; 15(11):1378-9. PubMed ID: 19965562
    [No Abstract] [Full Text] [Related]

  • 24. The cost of delaying treatment in multiple sclerosis: what is lost is not regained.
    Zwibel H.
    Neurology; 2002 Feb 26; 58(4):667; author reply 668. PubMed ID: 11865160
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.
    Bourdette D, Hartung D.
    JAMA Neurol; 2015 Dec 26; 72(12):1411-3. PubMed ID: 26457848
    [No Abstract] [Full Text] [Related]

  • 27. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS, Narayana PA, Johnson KP, Multiple Sclerosis Study Group and the MRI Analysis Center.
    Mult Scler; 2001 Feb 26; 7(1):33-41. PubMed ID: 11321192
    [Abstract] [Full Text] [Related]

  • 28. Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate.
    Windhagen A, Maniak S, Marckmann S, Lindert RB, Heidenreich F, Blasczyk R.
    J Neurol Neurosurg Psychiatry; 2001 Mar 26; 70(3):415-6. PubMed ID: 11181881
    [No Abstract] [Full Text] [Related]

  • 29. Psychiatric manifestations in multiple sclerosis patients and multiple sclerosis in psychiatric patient.
    Fragoso YD, Brooks JB.
    Arq Neuropsiquiatr; 2009 Dec 26; 67(4):1167-8. PubMed ID: 20069241
    [No Abstract] [Full Text] [Related]

  • 30. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Richert ND.
    Neurology; 2002 May 14; 58(9):1440-1; author reply 1441-2. PubMed ID: 12011306
    [No Abstract] [Full Text] [Related]

  • 31. Systemic reaction to glatiramer acetate.
    Bayerl C, Bohland P, Jung EG.
    Contact Dermatitis; 2000 Jul 14; 43(1):62-3. PubMed ID: 10902605
    [No Abstract] [Full Text] [Related]

  • 32. Glatiramer: a second look. With longer follow-up: still no proven benefit in multiple sclerosis.
    Prescrire Int; 2009 Dec 14; 18(104):252. PubMed ID: 20025092
    [No Abstract] [Full Text] [Related]

  • 33. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
    Oger J, Freedman M.
    Can J Neurol Sci; 1999 Nov 14; 26(4):274-5. PubMed ID: 10610197
    [No Abstract] [Full Text] [Related]

  • 34. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN, Kasatkin DS, Stepanov IO, Shipova EG, Baranova NS.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012 Nov 14; 112(8):27-33. PubMed ID: 23096035
    [Abstract] [Full Text] [Related]

  • 35. Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.
    Weiner HL.
    Proc Natl Acad Sci U S A; 1999 Mar 30; 96(7):3333-5. PubMed ID: 10097037
    [No Abstract] [Full Text] [Related]

  • 36. A 29-year-old man with multiple sclerosis, 1 year later.
    Delbanco TL, Hartman EE.
    JAMA; 1999 Mar 30; 281(24):2329. PubMed ID: 10386558
    [No Abstract] [Full Text] [Related]

  • 37. Glatiramer acetate in the treatment of multiple sclerosis.
    Miller AE.
    Neurol Clin; 2005 Feb 30; 23(1):215-31, viii. PubMed ID: 15661095
    [No Abstract] [Full Text] [Related]

  • 38. Editorial: the pitfalls of combination therapy.
    Vermersch P.
    Int MS J; 2006 Nov 30; 13(3):75-6. PubMed ID: 17101074
    [No Abstract] [Full Text] [Related]

  • 39. Glatiramer acetate-induced hepatitis in a patient with multiple sclerosis.
    Flaire A, Carra-Dalliere C, Ayrignac X, Blanc P, Labauge P.
    Acta Neurol Belg; 2016 Mar 30; 116(1):99-100. PubMed ID: 26141739
    [No Abstract] [Full Text] [Related]

  • 40. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
    Sørensen PS.
    Nat Rev Neurol; 2016 Jan 30; 12(1):5-6. PubMed ID: 26635211
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.